LON:IMM

ImmuPharma Final Earnings Results & Report

ImmuPharma logo
GBX 2.90 +0.49 (+20.37%)
As of 11:58 AM Eastern

ImmuPharma reported Final earnings on May 19, 2025. The company reported EPS of -GBX 0.60.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

ImmuPharma EPS Results

Actual EPS
-GBX 0.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ImmuPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

ImmuPharma Final Earnings FAQ

ImmuPharma (LON:IMM) reported earnings of -GBX 0.60 per share for Final. The report was announced on Monday, May 19, 2025.

ImmuPharma Earnings Headlines

This is likely to EXPLODE
Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.tc pixel
See More ImmuPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuPharma and other key companies, straight to your email.

About ImmuPharma

ImmuPharma (LON:IMM) (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

View ImmuPharma Profile